HUTCHMED's shares surged 17.77% after announcing a major licensing deal with GSK for its preclinical cancer drug HMPL-A830. GSK gets exclusive rights outside Greater China, paying $110 million upfront plus up to $1.295 billion in milestone payments. HUTCHMED retains rights in key Asian markets, highlighting strong growth potential. Analysts upgraded HUTCHMED to 'Buy,' citing the deal's value and the company's promising oncology pipeline.
Estée Lauder Companies recently appointed new brand leaders, signaling strategic shifts in its competitive beauty market. An insider executive sold 7,766 shares worth over $802,000, leaving no remaining holdings. The company shows a high P/E ratio of...
Genesco reported second-quarter earnings that surpassed analyst expectations, with an EPS loss of $0.83 versus the estimated loss of $1.37 per share. Although revenue fell 3% year-over-year to $529.86 million, the company improved its adjusted gross ...
Samsara Inc. will release its Q3 2026 earnings on September 3 after market close, with analysts expecting an EPS of $0.16 and revenue around $483 million. The company has a strong record of beating earnings estimates, with a 41.4% average surprise in...
Brady Corporation reported a strong fourth quarter with adjusted EPS of $1.48, beating analyst estimates and marking a 17.5% increase from last year. Revenue rose 10% to $436.9 million, driven by organic sales growth and acquisitions, including the r...
Telsey Advisory lowered G-III Apparel Group's price target from $38 to $32, reflecting mixed financial results and challenges integrating the Marc Jacobs brand. The company's net sales dropped from $613.3 million to $554.1 million, but GAAP net incom...
